March 15, 2026 a 03:43 pm
GILD: Fundamental Ratio Analysis - Gilead Sciences, Inc.
Gilead Sciences, Inc. has a strong position in the biopharmaceutical sector with its innovative treatments in HIV/AIDS and liver diseases. Recent fundamental analysis shows promising scores, indicating stability and growth potential. However, the debt-to-equity ratio remains a concern, necessitating careful monitoring.
Fundamental Rating
The current fundamental data suggests strong performance in key areas, though there is room for improvement in debt management.
| Category | Score | Visualization |
|---|---|---|
| Overall Score | 3 | |
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
Comparing the recent scores with past data illustrates stability in core areas while pointing to possible challenges in debt management.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-13 | 3 | 4 | 5 | 5 | 1 | 2 | 1 |
| N/A | 0 | 4 | 5 | 5 | 1 | 2 | 1 |
Analyst Price Targets
Analysts' estimates reflect a strong upside potential, though varying perspectives underscore the need for careful consideration of market risks.
| High | Low | Median | Consensus |
|---|---|---|---|
| $180 | $105 | $162 | $158.71 |
Analyst Sentiment
The sentiment among analysts is predominantly positive, with a majority recommending a 'Buy' stance, reflecting confidence in the company's future prospects.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 37 | |
| Hold | 20 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Gilead Sciences, Inc. features a solid portfolio in the biopharmaceutical industry, with strong financial fundamentals and favorable analyst projections. Despite its robust return metrics, attention is imperative due to its suboptimal debt-to-equity ratio. While mainly seen as a 'Buy', risk factors, including market volatility and strategic execution, should be closely monitored to mitigate potential downsides.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years